Otonomy (OTIC) Reports Q3 Loss of $0.57/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Otonomy (OTIC) Reports Q3 Loss of $0.57/Share
November 10, 2015 4:21 PM EST
SAN DIEGO, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financial results for the quarter ended September 30, 2015 and provided an update on its corporate activities and product pipeline.
Third Quarter 2015 and Subsequent Highlights
Completed Successful End-of-Phase 2 Meeting with the FDA for OTO-104 and Finalized Design of Phase 3 Clinical Program in Ménière's Disease: In September 2015, Otonomy announced the completion of a successful...
More
November 10, 2015 4:21 PM EST
SAN DIEGO, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financial results for the quarter ended September 30, 2015 and provided an update on its corporate activities and product pipeline.
Third Quarter 2015 and Subsequent Highlights
Completed Successful End-of-Phase 2 Meeting with the FDA for OTO-104 and Finalized Design of Phase 3 Clinical Program in Ménière's Disease: In September 2015, Otonomy announced the completion of a successful...
More
